Kopran: Medicine Authority European Union (EU)- conducted GMP inspection at Company's Formulation manufacturing…
Kopran (KOPRAN) filed a disclosure titled "Medicine Authority European Union (EU)- conducted GMP inspection at Company's Formulation manufacturing facility located at Khopoli is successfully concluded". The company is valued at about ₹1,311 crore.
What happened
Kopran (KOPRAN) filed a disclosure with the exchanges on 22 October 2026 at 01:01 PM titled "Medicine Authority European Union (EU)- conducted GMP inspection at Company's Formulation manufacturing facility located at Khopoli is successfully concluded".
Company snapshot
Kopran is a small-cap company, with a market value of about ₹1,311 crore.
The stock last traded at ₹271.6, against a 52-week range of ₹107–₹295.8 (8.2% below the high).
Before this filing the shares had moved −4.9% over the month and +31.1% over three months. Average daily turnover over the last 20 sessions was about ₹16.12 crore.
Promoters held 44.42% at the end of Q1 FY27. Foreign institutions owned 0.51% and domestic institutions 0.00%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 135 | 7.4 | 1.54 |
| Q2 FY26 | 118 | -9.9 | -2.06 |
| Q3 FY26 | 194 | 9.3 | 1.93 |
| Q4 FY26 | 234 | 18.9 | 3.91 |
| Q1 FY27 | 154 | 6.7 | 1.39 |
What history shows
BCEIE has no earlier approval filing from this company on record since May 2026.
Market-wide, 1,513 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.